Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-302trelanemabEarly Alzheimer's diseaseNeuroscience · Antibody
Subcutaneous form in Phase 3
CLV-310Parkinson's diseaseNeuroscience · Small molecule
Phase 3 readout 2027
CLV-318Treatment-resistant depressionNeuroscience · Small molecule
Phase 2 data Q1 2027
CLV-325ALSNeuroscience · RNA
Candidate selected
Pipeline as of September 30, 2026. Programs and data are fictional.